Roundhill Magnificent Seven ETF vs 22nd Century Group Inc — how do they compare? Roundhill Magnificent Seven ETF trades at $73.7 (market cap $5.78B), while 22nd Century Group Inc trades at $0.8 (market cap $621.67K). The key difference: Roundhill Magnificent Seven ETF is far larger — about 9297.5× 22nd Century Group Inc's market cap, and Roundhill Magnificent Seven ETF is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Roundhill Magnificent Seven ETF for 36 Days and 22nd Century Group Inc for 32 Days on average.
| MAGS | XXII | |
|---|---|---|
Market Cap | $5.78B | $621.67K |
Volume | 4,410,665 | 45,625 |
Sector | Sector/Thematic | Consumer Staples |
52-Week High | $73.90 | $483.00 |
52-Week Low | $55.39 | $0.80 |
Typical Hold Time | 36 Days | 32 Days |
Enterprise Value | — | -$3.69M |
Signals from Pluang's Aura AI — not financial advice
MAGS trades at $73.66, showing minimal daily movement with a slight 0.04% decline. Technical indicators signal a bullish trend with strong moving average support, while oscillators remain neutral. The ETF provides equal-weighted exposure to the Magnificent Seven mega-cap tech stocks, though recent performance has trailed broader market indexes with modest 2% year-to-date gains.
The outlook remains cautiously optimistic given the ETF's concentrated tech exposure and AI growth themes. Key risks include market concentration, valuation concerns, and potential regulatory scrutiny. Wall Street sentiment appears mixed as investors weigh long-term AI potential against near-term performance challenges.
22nd Century Group (XXII) trades at $0.89, down 0.94% today, with a bearish technical signal despite oversold RSI readings. The company shows severe financial stress with negative gross margins of -54.6% and net income margin of -76.01%, though valuation metrics appear low with P/S of 0.09 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives and expanded retail distribution for VLN products.
While analyst consensus remains bullish with 75% buy ratings and a $1,240 price target, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock presents high-risk speculation on regulatory adoption of reduced-nicotine standards, requiring careful risk assessment given the company's ongoing losses and cash burn.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →